PB

Prestige Consumer Healthcare IncFRA Prestige Consumer Stock Report

Last reporting period 30 Sep, 2024

Updated 12 Nov, 2024

Last price

Market cap $B

3.525

Middle

Exchange

XFRA - Deutsche Boerse AG

PBV.F Stock Analysis

PB

Avoid

Based on Eyestock quantitative analysis, PBV.F`s fundamental data and valuation indicate an investment grade of Avoid at the current time.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

59/100

Moderate score

Upside

To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.

-25.6 %

Greatly overvalued

Market cap $B

3.525

Dividend yield

Shares outstanding

49.688 B

Prestige Consumer Healthcare, Inc. engages in the marketing, sale, and distribution of pharmaceutical drugs and consumer products. The company is headquartered in Tarrytown, New York and currently employs 535 full-time employees. The company went IPO on 2005-02-10. The firm operates through two segments: North American OTC Healthcare and International OTC Healthcare. Its brands include BC/Goody's, Boudreaux's Butt Paste, Chloraseptic, Clear Eyes, Compound W, Debrox, DenTek, Dramamine, Fleet, Gaviscon, Luden's, Monistat, Nix, TheraTears, Summer's Eve, Fess and Hydralyte. Its subsidiaries include Blacksmith Brands, Inc., C.B. Fleet Company, Incorporated, Care Pharmaceuticals Pty Limited, DenTek Holdings, Inc., Medtech Holdings, Inc., Peaks HBC Company, Inc. and others.

View Section: Eyestock Rating